Total Payments
$48,966
2024 Payments
$258.09
Companies
10
Transactions
53
Medicare Patients
279
Medicare Billing
$101,923
Payment Breakdown by Category
Consulting$36,563 (74.7%)
Travel$4,177 (8.5%)
Other$3,200 (6.5%)
Research$2,866 (5.9%)
Food & Beverage$2,161 (4.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $36,563 | 6 | 74.7% |
| Travel and Lodging | $4,177 | 16 | 8.5% |
| Honoraria | $3,200 | 1 | 6.5% |
| Unspecified | $2,866 | 1 | 5.9% |
| Food and Beverage | $2,161 | 29 | 4.4% |
Payments by Type
General
$46,100
52 transactions
Research
$2,866
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $25,344 | 35 | $0 (2023) |
| Vertex Pharmaceuticals Incorporated | $16,577 | 6 | $0 (2023) |
| Spectrum Pharmaceuticals Inc. | $3,528 | 4 | $0 (2017) |
| Celgene Corporation | $2,866 | 1 | $0 (2018) |
| GENZYME CORPORATION | $129.85 | 1 | $0 (2024) |
| bluebird bio, Inc. | $128.24 | 1 | $0 (2024) |
| Amgen Inc. | $120.00 | 1 | $0 (2018) |
| Jazz Pharmaceuticals Inc. | $113.63 | 1 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $104.39 | 1 | $0 (2018) |
| Kite Pharma, Inc. | $55.49 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $258.09 | 2 | GENZYME CORPORATION ($129.85) |
| 2023 | $27,142 | 18 | Vertex Pharmaceuticals Incorporated ($16,577) |
| 2019 | $29.28 | 1 | Kite Pharma, Inc. ($29.28) |
| 2018 | $11,975 | 16 | Incyte Corporation ($8,859) |
| 2017 | $9,562 | 16 | Incyte Corporation ($5,920) |
All Payment Transactions
53 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $129.85 | General |
| Category: Oncology | ||||||
| 06/05/2024 | bluebird bio, Inc. | LYFGENIA (Drug) | Food and Beverage | In-kind items and services | $128.24 | General |
| Category: sickle-cell | ||||||
| 08/03/2023 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $14,950.00 | General |
| 08/03/2023 | Vertex Pharmaceuticals Incorporated | — | Travel and Lodging | In-kind items and services | $756.94 | General |
| 08/03/2023 | Vertex Pharmaceuticals Incorporated | — | Travel and Lodging | In-kind items and services | $531.10 | General |
| 08/03/2023 | Vertex Pharmaceuticals Incorporated | — | Travel and Lodging | In-kind items and services | $193.65 | General |
| 08/03/2023 | Vertex Pharmaceuticals Incorporated | — | Food and Beverage | In-kind items and services | $80.00 | General |
| 08/03/2023 | Vertex Pharmaceuticals Incorporated | — | Food and Beverage | In-kind items and services | $65.00 | General |
| 06/13/2023 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $425.00 | General |
| 04/11/2023 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $4,037.50 | General |
| 01/12/2023 | Incyte Corporation | JAKAFI (Drug) | Consulting Fee | Cash or cash equivalent | $4,850.00 | General |
| Category: Hematology/Oncology | ||||||
| 01/12/2023 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $93.14 | General |
| Category: Hematology/Oncology | ||||||
| 01/12/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $85.87 | General |
| Category: Hematology/Oncology | ||||||
| 01/12/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $80.00 | General |
| Category: Hematology/Oncology | ||||||
| 01/12/2023 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $67.15 | General |
| Category: Hematology/Oncology | ||||||
| 01/12/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $52.18 | General |
| Category: Hematology/Oncology | ||||||
| 01/12/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.01 | General |
| Category: Hematology/Oncology | ||||||
| 01/11/2023 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $579.73 | General |
| Category: Hematology/Oncology | ||||||
| 01/11/2023 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $225.94 | General |
| Category: Hematology/Oncology | ||||||
| 01/11/2023 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $50.57 | General |
| Category: Hematology/Oncology | ||||||
| 08/05/2019 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $29.28 | General |
| Category: ONC | ||||||
| 10/19/2018 | Amgen Inc. | Kyprolis (Biological) | Food and Beverage | In-kind items and services | $120.00 | General |
| Category: Oncology | ||||||
| 06/05/2018 | Merck Sharp & Dohme Corporation | PREVYMIS (Drug) | Food and Beverage | In-kind items and services | $104.39 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/30/2018 | Celgene Corporation | Revlimid (Drug) | — | In-kind items and services | $2,866.00 | Research |
| Study: RV-MM-PI-0385 - A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma • Category: Hematology / Oncology | ||||||
| 05/17/2018 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $26.21 | General |
| Category: ONC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RV-MM-PI-0385 - A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma | Celgene Corporation | $2,866 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 68 | 246 | $129,400 | $29,891 |
| 2022 | 3 | 54 | 172 | $83,758 | $18,342 |
| 2021 | 4 | 83 | 253 | $122,580 | $30,766 |
| 2020 | 4 | 74 | 209 | $91,005 | $22,925 |
Total Patients
279
Total Services
880
Medicare Billing
$101,923
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 28 | 127 | $51,210 | $13,467 | 26.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 29 | 72 | $53,280 | $11,232 | 21.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 11 | 47 | $24,910 | $5,193 | 20.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 23 | 111 | $43,028 | $9,682 | 22.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 17 | 40 | $29,600 | $6,374 | 21.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 14 | 21 | $11,130 | $2,286 | 20.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 30 | 138 | $53,820 | $13,241 | 24.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 22 | 69 | $43,240 | $11,150 | 25.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 19 | 34 | $15,920 | $4,139 | 26.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 12 | 12 | $9,600 | $2,236 | 23.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 28 | 125 | $46,475 | $12,056 | 25.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 20 | 45 | $22,950 | $5,914 | 25.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 14 | 26 | $11,180 | $2,663 | 23.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 13 | $10,400 | $2,292 | 22.0% |
About Dr. Markus Mapara, M.D
Dr. Markus Mapara, M.D is a Hematology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093786766.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Markus Mapara, M.D has received a total of $48,966 in payments from pharmaceutical and medical device companies, with $258.09 received in 2024. These payments were reported across 53 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($36,563).
As a Medicare-enrolled provider, Mapara has provided services to 279 Medicare beneficiaries, totaling 880 services with total Medicare billing of $101,923. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology, Hematology & Oncology
- Location New York, NY
- Active Since 01/30/2006
- Last Updated 03/24/2023
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1093786766
Products in Payments
- JAKAFI (Drug) $12,137
- Evomela (Drug) $3,528
- Revlimid (Drug) $2,866
- SARCLISA (Biological) $129.85
- LYFGENIA (Drug) $128.24
- Kyprolis (Biological) $120.00
- Defitelio (Drug) $113.63
- PREVYMIS (Drug) $104.39
- Yescarta (Drug) $55.49
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in New York
Dr. Barry Coller, M.d, M.D
Hematology — Payments: $10.2M
Hematology $10.2M
Dr. Dan Douer, M.d, M.D
Hematology — Payments: $665,161
Hematology $665,161
Louis Aledort, Md, MD
Hematology — Payments: $377,491
Hematology $377,491
Michael Mauro, Md, MD
Hematology — Payments: $374,307
Hematology $374,307
Faith Davies, Md, MD
Hematology — Payments: $373,421
Hematology $373,421
Ann Jakubowski, Md, MD
Hematology — Payments: $92,726
Hematology $92,726